A Message From Our Program Leader
We are dedicated to advancing care in gastrointestinal and immune-mediated diseases. We lead clinical research focused on expanding treatment options for patients facing complex and often non-curable conditions. Participation in our trials offers enhanced oversight, more frequent monitoring, and access to emerging therapies.
For patients with limited options or who have not responded to standard treatments, our goal is to improve quality of life and work toward disease control or remission through innovative, evidence-based approaches.
About Our Program
The Gastroenterology Program is committed to advancing device- and drug-based therapies for a range of conditions, including inflammatory bowel disease (IBD), autoimmune disorders, gastroesophageal reflux disease (GERD), esophageal diseases, and emerging liver conditions, such as metabolic dysfunction-associated steatohepatitis (MASH).
Our research integrates procedural and pharmacologic approaches, providing patients with access to cutting-edge clinical trials and personalized care. Participation in these trials offers enhanced oversight, more frequent monitoring, and early access to investigational treatments. The GI research team is focused on improving outcomes and expanding therapeutic options for patients with complex gastrointestinal and immune-mediated conditions. We actively collaborate with the surgical and interventional GI programs, as well as other research divisions, recognizing that gastrointestinal health—particularly the stomach and gut microbiome—has a significant impact on multiple body systems, including immune, neurological, and metabolic pathways.
Gastroenterology Research Facts and Figures
IBD (Inflammatory Bowel Disease) affects an estimated 2.4 to 3.1 million people in the U.S., with disparities in burden across populations, underscoring the need for inclusive, targeted research.